QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

RARE

QT77Ultragenyx Pharmaceutical Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
27.44
+0.53+1.97%
OverviewShort InterestFilings
RAREQT77Ultragenyx Pharmaceutical Inc.·NASDAQ
OverviewShort InterestFilings
27.44+1.97%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-6.11
Insider Own4.12%
Shs Outstand98.49M
Perf Week14.43%
Market Cap2.65BForward P/E-EPS next Y-0.70Insider Trans-0.14%Shs Float-Perf Month22.23%
Enterprise Value3.68BPEG0.91EPS next Q-1.24Inst Own-Short Float-Perf Quarter34.38%
Income-596592518.00P/S3.96EPS this Y26.64%Inst Trans-Short Ratio-Perf Half Y-20.09%
Sales669.43MP/B-EPS next Y84.40%ROA-47.02%Short Interest-Perf YTD19.30%
Book/sh-2.33P/C-EPS next 5Y-ROE1566.94%52W High42.37 -35.24%Perf Year-25.15%
Cash/sh4.19P/FCF-EPS past 3/5Y-ROIC-53.86%52W Low18.29 50.03%Perf 3Y-
Dividend Est.-EV/EBITDA-7.30Sales past 3/5Y22.85% 19.95%Gross Margin83.57%Volatility3.57% 3.14%Perf 5Y-
Dividend TTM-EV/Sales5.49EPS Y/Y TTM2.86%Oper. Margin-83.92%ATR (14)1.27Perf 10Y-
Dividend Ex-Date-Quick Ratio1.85Sales Y/Y TTM19.46%Profit Margin-91.03%RSI (14)66.71Recom2.25
Dividend Gr. 3/5Y-Current Ratio2.02EPS Q/Q-17.20%SMA2015.94%Beta1.35Target Price48.36
Payout0.00%Debt/Eq-5.08Sales Q/Q-2.16%SMA5012.83%Rel Volume2.05Prev Close26.91
Employees1,294LT Debt/Eq-16.37EarningsAug 04SMA2001.51%Avg Volume1.74MPrice27.44
IPO DateJan 31, 2014Option/ShortYes / YesEPS/Sales Surpr.-23.67% -13.92%Net Debt/EBITDA-2.04Volume3,562,375Change1.97%
Analyst Ratings
DateActionAnalystRatingTarget
May-08-26ReiteratedWedbushNeutral$27 → $26
May-08-26ReiteratedGuggenheimBuy$52 → $43
Apr-29-26ReiteratedBarclaysOverweight$44 → $43
Apr-16-26ReiteratedMorgan StanleyOverweight$50 → $67
Mar-12-26ReiteratedLeerink Partners$85 → $60
Feb-18-26ReiteratedEvercore ISI$37 → $34
Feb-17-26ReiteratedEvercore ISI$39 → $37
Feb-17-26ReiteratedH.C. WainwrightNeutral$60 → $50
Feb-13-26ReiteratedGoldman SachsBuy$71 → $61
Feb-13-26ReiteratedRobert W. Baird$47 → $40
Latest News
Jun-17-26
Jun-17-2601:33PM
Small Caps Near Record Highs, Robinhood Rallies 12%: Stock Market TodayBenzinga
10:11AM
Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On WednesdayBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue669673560
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A11010977
Gross Profit559564484
Selling, General and Administrative Excl. Other351349322
Research and Development771750698
Other Operating Expense-10-1
Operating Income-562-535-536
Interest Expense686263
Unusual Expense
———
Non-Operating Income (Expense)-24-26-31
Net Income Before Taxes-606-571-568
Income Taxes442
Consolidated Net Income-609-575-569
Net Income From Continuing Operations-609-575-569
Net Income-609-575-569
EPS (Recurring)-6.11-5.83-6.29
EPS (Basic, Before Extraordinaries)-6.11-5.83-6.29
EPS (Diluted)-6.11-5.83-6.29
EBITDA-503-474-469
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio4.143.38—
Gross Margin83.5683.8086.43
Operating Margin-84.01-79.49-95.71
Net Margin-91.03-85.44-101.61
Shares Outstanding1019991
Market Capitalization2,7712,277—
Operating Lease Expense
———
Insider Trading Volume
$30.03$28.41$26.78$25.16$23.53● Close Price0.00M0.63M1.26M1.90M2.53MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Sanders Corazon (Corsee) D.DirectorJun 15 '26Sale25.052,00050,10021,095Jun 15 12:00 AM
Parschauer Karah HerdmanEVP and Chief Legal OfficerJun 15 '26Sale24.621,89946,75394,462Jun 15 12:00 AM
Horn HowardChief Financial OfficerJun 01 '26Sale23.774,653110,602105,689Jun 01 12:00 AM
SULIMAN SHEHNAAZDirectorMay 18 '26Sale25.125,740144,18927,951May 18 12:00 AM
Crombez EricEVP and Chief Medical OfficerMay 05 '26Sale24.963448,586111,189May 06 12:00 AM
Horn HowardChief Financial OfficerMay 01 '26Sale24.904,683116,607110,342May 04 12:00 AM
Horn HowardChief Financial OfficerApr 01 '26Sale20.974,68398,20380,351Apr 02 12:00 AM
Parschauer Karah HerdmanEVP and Chief Legal OfficerMar 10 '26Sale22.673,50879,52666,820Mar 10 12:00 AM
Parschauer Karah HerdmanEVP and Chief Legal OfficerMar 06 '26Sale21.406,018128,78570,328Mar 10 12:00 AM
Horn HowardChief Financial OfficerMar 03 '26Sale22.401,63536,62485,034Mar 03 12:00 AM
Parschauer Karah HerdmanEVP and Chief Legal OfficerMar 02 '26Sale22.808,135185,47876,346Mar 03 12:00 AM
Pinion John RichardSee RemarksMar 02 '26Sale22.8010,029228,661110,026Mar 03 12:00 AM
Harris ErikEVP & Chief Commercial OfficerMar 02 '26Sale22.8010,539240,28989,515Mar 03 12:00 AM
KAKKIS EMIL DPresident & CEOMar 02 '26Sale22.8054,4041,240,411658,994Mar 03 12:00 AM
Crombez EricEVP and Chief Medical OfficerMar 02 '26Sale22.807,029160,26176,301Mar 03 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR